ACUSENSUS LIMITED (ACE)
Share Price Analysis and Chart

27/02/2026

1

Speculative Buy

$2.30

56.46%

Acusensus delivered a strong 1H26 result, with revenue up 40% y.y in line with Morgans, and adjusted EBITDA up 9%, supported by new contract ramp up in New Zealand and Western Australia.

The International segment delivered positive EBITDA of $0.9m for the first time, while operating cash flow was $1.3m and the balance sheet strengthened to $41.0m cash following a $30.0m equity raise and new debt facility.

FY26 revenue guidance and EBITDA were reaffirmed, implying stronger 2H momentum from full run rate contracts and further domestic expansion.

Earnings forecasts are tweaked higher. Speculative Buy retained with a $2.30 target price

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.70 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -3.00 cents.

09/03/2026

1

Buy

$2.50

70.07%

Acusensus delivered a first half result that was in line with estimates and reiterated FY26 guidance for revenue to increase 40-46% to $83-87m.

The company is investing, increasing its "innovation activities" to $4m with operating and capital expenditure stepping up to -$22m, announcing the expansion of its multifunction fixed enforcement contract in Western Australia with incremental value of $11m to the original contract worth $9m.

Canaccord Genuity asserts the business has a bespoke, proprietary and industry-specific AI model that should provide significant protection against potential competitor-driven disruption. Buy rating unchanged. Target rises to $2.50 from $2.30.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents.